This article presents the synthesis and characterization of biocompatible superparamagnetic iron oxide nanoparticles (SPIONs) coated with ultrathin layer of anionic derivative of chitosan. The water-based fabrication involved a two-step procedure. In the first step, the nanoparticles were obtained by co-precipitation of ferrous and ferric aqueous salt solutions with ammonia in the presence of cationic derivative of chitosan. In the second step, such prepared materials were subjected to adsorption of oppositely charged chitosan derivative which resulted in the preparation of negatively charged SPIONs. They were found to develop highly stable dispersion in water. The core size of the nanocoated SPIONs, determined using transmission electron microscopy, was measured to be slightly above 10 nm. The coated nanoparticles form aggregates with majority of them having hydrodynamic diameter below 100 nm, as measured by dynamic light scattering. Their composition and properties were studied using FTIR and thermogravimetric analyses. They exhibit magnetic properties typical for superparamagnetic material with a high saturation magnetization value of 123 ± 12 emu g−1 Fe. Very high value of the measured r2 relaxivity, 369 ± 3 mM−1 s−1, is conducive for the potential application of the obtained SPIONs as promising contrast agents in magnetic resonance imaging.Electronic supplementary materialThe online version of this article (doi:10.1007/s11051-012-1372-9) contains supplementary material, which is available to authorized users.
Here, we analyzed systemic (plasma) and local (heart/aorta) changes in ACE/ACE-2 balance in Tgαq*44 mice in course of heart failure (HF). Tgαq*44 mice with cardiomyocyte-specific Gαq overexpression and late onset of HF were analyzed at different age for angiotensin pattern in plasma, heart, and aorta using liquid chromatography/mass spectrometry, for progression of HF by in vivo magnetic resonance imaging under isoflurane anesthesia, and for physical activity by voluntary wheel running. Six-month-old Tgαq*44 mice displayed decreased ventricle radial strains and impaired left atrial function. At 8-10 mo, Tgαq*44 mice showed impaired systolic performance and reduced voluntary wheel running but exhibited preserved inotropic reserve. At 12 mo, Tgαq*44 mice demonstrated a severe impairment of basal cardiac performance and modestly compromised inotropic reserve with reduced voluntary wheel running. Angiotensin analysis in plasma revealed an increase in concentration of angiotensin-(1-7) in 6- to 10-mo-old Tgαq*44 mice. However, in 12- to 14-mo-old Tgαq*44 mice, increased angiotensin II was noted with a concomitant increase in Ang III, Ang IV, angiotensin A, and angiotensin-(1-10). The pattern of changes in the heart and aorta was also compatible with activation of ACE2, followed by activation of the ACE pathway. In conclusion, mice with cardiomyocyte Gαq protein overexpression develop HF that is associated with activation of the systemic and the local ACE/Ang II pathway. However, it is counterbalanced by a prominent ACE2/Ang-(1-7) activation, possibly allowing to delay decompensation. NEW & NOTEWORTHY Changes in ACE/ACE-2 balance were analyzed based on measurements of a panel of nine angiotensins in plasma, heart, and aorta of Tgαq*44 mice in relation to progression of heart failure (HF) characterized by multiparametric MRI and exercise performance. The early stage of HF was associated with upregulation of the ACE2/angiotensin-(1-7) pathway, whereas the end-stage HF was associated with downregulation of ACE2/angiotensin-(1-7) and upregulation of the ACE/Ang II pathway. ACE/ACE-2 balance seems to determine the decompensation of HF in this model.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.